Basecamp Research Integrates EDEN Models with Claude Science
LONDON and CAMBRIDGE, Mass., June 30, 2026 — Basecamp Research today announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude, including Claude Science, Anthropic’s AI workbench for life sciences research. This integration allows researchers to generate and prioritise therapeutic candidates through a conversational interface in a matter of minutes.
By combining Claude’s reasoning capabilities with EDEN’s biological design capabilities, researchers can go directly from a target to a shortlist of high-performing antibiotic or vaccine candidates. This capability is available across Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork, and Claude Science through Anthropic’s connectors directory.
The Urgent Need for New Antibiotics
Drug-resistant infections play a role in nearly 5 million deaths per year, yet the pharmaceutical industry has largely retreated from antibiotic development. New antibiotics are desperately needed, especially for pathogens spreading fastest in lower-income countries where last-resort drugs are hardest to access.
“Microbes have been producing antibiotics and evolving resistance to each other for billions of years,” said Glen Gowers, Co-founder and CEO of Basecamp Research. “EDEN learned from that history, and now, through Claude, researchers all over the world can design successful new antibiotics in minutes, not years.”
Proven Efficacy in Lab Tests
In collaboration with researchers at the University of Pennsylvania, Basecamp Research demonstrated that 97% of the antibiotic peptides designed by EDEN are active against World Health Organisation (WHO) priority pathogens when tested in the lab. Fleming Prize winner and Presidential Associate Professor César de la Fuente led the work by UPenn’s Machine Biology Group.
One candidate, EDEN-7, was tested in mice infected with multidrug-resistant Acinetobacter baumannii – a pathogen associated with hospital outbreaks worldwide – and showed efficacy in the same range as a last-line antibiotic, despite being generated zero-shot, meaning the model produced it without subsequent optimization or iterative engineering.
“This collaboration shows how frontier biological foundation models can be paired with rigorous experimental validation to accelerate antibiotic discovery,” de la Fuente said. “Antimicrobial resistance is one of the greatest existential threats facing humanity and collaborations like this between academia and industry are critical.”
Rapid Vaccine Target Prioritisation
Developing a vaccine against an emerging pathogen is a race against time. Which part of the pathogen to target is often determined empirically, which can take months of laboratory work. This delay often costs lives.
EDEN’s vaccine design model identifies which proteins are most likely to trigger a protective immune response, outperforming comparable genomic foundation models. By integrating it into Claude, researchers can describe a problem in plain language and have Claude run a prioritisation workflow against the pathogen’s genetic sequence. This can reduce several weeks of research per pathogen into a single conversation.
